U.S. drugmakers Merck and Moderna said Wednesday that an experimental, personalized mRNA-based therapy reduced melanoma recurrence in a late-stage clinical trial [1, 5].
The results represent a potential shift in how physicians treat high-risk skin cancer patients. By tailoring the treatment to the individual, the therapy aims to prevent the disease from returning after initial treatment [3, 5].
The treatment is described as a personalized mRNA-based drug or vaccine [1, 3]. It is designed specifically for patients at high risk of the cancer returning, using the patient's own genetic data to create a tailored response [4, 5].
While some reports categorize the therapy as an experimental melanoma drug [1], others identify it as a vaccine for melanoma recurrence [3]. This distinction reflects the dual nature of mRNA technology, which can act as both a therapeutic drug and a preventative vaccine by instructing the immune system to recognize specific cancer markers [4].
Merck and Moderna said they developed the therapy as a collaborative effort to curb the risk of recurrence [1, 2]. The late-stage trial focused on whether this tailored approach could offer better protection than standard care alone [5].
Researchers focused on the ability of the mRNA sequence to target mutations unique to each patient's tumor [4]. This personalization is intended to minimize side effects while maximizing the immune system's ability to detect and destroy remaining cancer cells [5].
The companies said the findings in the United States on Aug. 19 [5]. This milestone follows years of research into mRNA applications beyond infectious diseases [4].
“An experimental, personalized mRNA-based melanoma drug/vaccine that prevents cancer recurrence”
The success of this trial suggests that personalized medicine—where treatments are engineered for a specific patient's genetic profile—could become a standard of care for oncology. By utilizing mRNA technology, which gained global prominence during the COVID-19 pandemic, Merck and Moderna are demonstrating that the platform can be adapted to treat complex chronic diseases, potentially reducing the reliance on broad-spectrum chemotherapy.
